Hartmann Elena, Fernàndez Verònica, Moreno Victor, Valls Joan, Hernández Luis, Bosch Francesc, Abrisqueta Pau, Klapper Wolfram, Dreyling Martin, Hoster Eva, Müller-Hermelink Hans Konrad, Ott German, Rosenwald Andreas, Campo Elías
Institute of Pathology, University of Würzburg, Würzburg, Germany.
J Clin Oncol. 2008 Oct 20;26(30):4966-72. doi: 10.1200/JCO.2007.12.0410. Epub 2008 Jul 7.
Despite the common underlying translocation t(11;14) involving cyclin D1 that is present in nearly all cases of mantle-cell lymphoma (MCL), the clinical course of the disease is highly variable. The aim of the present study was to develop a quantitative gene expression-based model to predict survival in newly diagnosed patients with MCL that involves a minimum number of genes and is applicable to fresh-frozen and formalin-fixed, paraffin-embedded (FFPE) tumor samples.
The expression of 33 genes with potential prognostic and pathogenetic impact in MCL was analyzed using quantitative reverse-transcription polymerase chain reactions (qRT-PCR) in a low-density array format in frozen tumor samples from 73 patients with MCL. Multivariate Cox methods and stepwise algorithms were applied to build gene expression-based survival predictors. An optimized five-gene model was subsequently applied to FFPE tumor samples from 13 patients with MCL from the initial series and to 42 independent MCL samples.
The optimized survival predictor was composed of the five genes RAN, MYC, TNFRSF10B, POLE2, and SLC29A2 and was validated for application in FFPE tissue samples. It allowed the survival prediction of patients with MCL with widely disparate clinical outcome and was superior to the immunohistochemical marker Ki-67, an established prognostic factor in MCL.
We here present a validated qRT-PCR-based test for survival prediction in patients with MCL that is applicable to fresh frozen as well as to FFPE tissue specimens. This test may prove useful to guide individualized treatment approaches for patients with MCL.
尽管套细胞淋巴瘤(MCL)几乎所有病例都存在涉及细胞周期蛋白D1的常见潜在易位t(11;14),但该疾病的临床病程高度可变。本研究的目的是建立一种基于基因表达定量的模型,以预测新诊断的MCL患者的生存情况,该模型涉及的基因数量最少,且适用于新鲜冷冻和福尔马林固定、石蜡包埋(FFPE)的肿瘤样本。
使用低密度阵列形式的定量逆转录聚合酶链反应(qRT-PCR)分析了73例MCL患者冷冻肿瘤样本中33个对MCL具有潜在预后和致病影响的基因的表达。应用多变量Cox方法和逐步算法构建基于基因表达的生存预测模型。随后将优化后的五基因模型应用于最初系列中13例MCL患者的FFPE肿瘤样本以及42个独立的MCL样本。
优化后的生存预测模型由RAN、MYC、TNFRSF10B、POLE2和SLC29A2这五个基因组成,并在FFPE组织样本中的应用得到验证。它能够预测临床结局差异很大的MCL患者的生存情况,并且优于免疫组化标志物Ki-67,后者是MCL中已确立的预后因素。
我们在此展示了一种经过验证的基于qRT-PCR的检测方法,用于预测MCL患者的生存情况,该方法适用于新鲜冷冻以及FFPE组织标本。该检测方法可能有助于指导MCL患者的个体化治疗方案。